Repare Therapeutics Inc (RPTX) Stock Price, Quote & News

Company Profile

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 412 7018

Website: www.reparerx.com

Address:

7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Montreal, Canada

q3qd Jan. 2 at 8:45 PM

$RPTX Expecting a gradual pump as Jan 16 gets closer but the share price will crater the moment cash payout occurs; however could be a very good swing trade long term.

0 · Reply

BillionerOfKing Jan. 2 at 2:04 AM

$RPTX Current Stock Price: $2.61 Contracts to trade: $2.5 RPTX Jan 16 2026 Call Entry: $0.10 Exit: $0.14 ROI: 41% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

JustGB Dec. 30 at 2:59 PM

$GLSI $DRTS $EKSO $RPTX

0 · Reply

JKtech Dec. 30 at 2:56 PM

The #Biotech "Ignition" Watchlist for Jan 2026. If you aren’t watching these 4 sleepers, you aren't paying attention. High-velocity catalysts incoming: $GLSI - Insiders just extended their lock-up to SEPT 2026. Why? Phase III Flamingo-01 data is hinting at 80% recurrence reduction. Smart money is staying put for the big win. $DRTS - The "coiled spring." J.P. Morgan Conference Jan 15. CEO update on Pancreatic & Glioblastoma data. Radiopharma is the white-hot M&A sector of 2026. $EKSO - Quietly beating EPS & revenue targets. Commercial AI-integration with NVIDIA is the sleeper hit of the med-tech space. Profitable pivot is in play. $RPTX - GIlead just bought their RP-3467 candidate for $30M upfront. Major validation of their platform. Cash-rich and ready to run into Q1. Volume is waking up. Don't chase the green candles—front-run the catalysts.

0 · Reply

kareem1988 Dec. 30 at 11:56 AM

Don't you love it when Stocktwits buzzing agrees with TradingView charts. That’s the sweet spot $EKSO $GLSI $DRTS $RPTX

2 · Reply

JohnTrack Dec. 29 at 4:06 PM

$RPTX no rush, just observing...

0 · Reply

JohnTrack Dec. 29 at 12:04 PM

$RPTX Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration https://www.rapidticker.com/news/rptx-sec-filing-4e1525

0 · Reply

Stock_Catcher Dec. 29 at 12:55 AM

Money Monday Watchlist Pt. 9 $NXDR $GLSI $GIPR $RPTX $SOAR Let's Find a 1000%+ Runner this Week

0 · Reply

littleharoldeh Dec. 28 at 4:50 PM

$RPTX So what's the point of investing here if they are gonnna delist and only gonna get $1.82 a share

1 · Reply

Freshyone Dec. 26 at 4:39 PM

$RPTX ~ Whales coming for 2.66 break🐳🎉

0 · Reply

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Nov 20, 2025, 5:25 PM EST - 6 weeks ago

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Nov 18, 2025, 7:44 AM EST - 7 weeks ago

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

SEE

Nov 17, 2025, 10:24 AM EST - 7 weeks ago

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

Nov 14, 2025, 4:44 PM EST - 7 weeks ago

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

Oct 13, 2025, 4:05 PM EDT - 3 months ago

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 8, 2025, 7:00 AM EDT - 5 months ago

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 15, 2025, 4:05 PM EDT - 6 months ago

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

May 13, 2025, 4:05 PM EDT - 8 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 8 months ago

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

May 1, 2025, 7:00 AM EDT - 8 months ago

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Apr 25, 2025, 1:00 PM EDT - 9 months ago

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Mar 31, 2025, 4:39 PM EDT - 10 months ago

Repare Therapeutics Announces Leadership Transitions

Mar 7, 2025, 4:05 PM EST - 10 months ago

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 7:05 AM EST - 11 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 9, 2025, 4:05 PM EST - 1 year ago

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Dec 13, 2024, 12:09 PM EST - 1 year ago

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Dec 12, 2024, 4:20 PM EST - 1 year ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Dec 10, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Nov 12, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Nov 7, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Oct 23, 2024, 6:05 AM EDT - 1 year ago

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Oct 14, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Sep 30, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Sep 23, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Aug 30, 2024, 6:13 PM EDT - 1 year ago

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Jun 26, 2024, 10:30 AM EDT - 1 year ago

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Jun 10, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

May 7, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Apr 26, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Appoints Steven H. Stein, M.D.

Mar 21, 2024, 10:00 AM EDT - 1 year ago

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 28, 2024, 7:05 AM EST - 2 years ago

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 7:05 AM EST - 2 years ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

q3qd Jan. 2 at 8:45 PM

$RPTX Expecting a gradual pump as Jan 16 gets closer but the share price will crater the moment cash payout occurs; however could be a very good swing trade long term.

0 · Reply

BillionerOfKing Jan. 2 at 2:04 AM

0 · Reply

JustGB Dec. 30 at 2:59 PM

$GLSI $DRTS $EKSO $RPTX

0 · Reply

JKtech Dec. 30 at 2:56 PM

0 · Reply

kareem1988 Dec. 30 at 11:56 AM

Don't you love it when Stocktwits buzzing agrees with TradingView charts. That’s the sweet spot $EKSO $GLSI $DRTS $RPTX

2 · Reply

JohnTrack Dec. 29 at 4:06 PM

$RPTX no rush, just observing...

0 · Reply

JohnTrack Dec. 29 at 12:04 PM

$RPTX Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration https://www.rapidticker.com/news/rptx-sec-filing-4e1525

0 · Reply

Stock_Catcher Dec. 29 at 12:55 AM

Money Monday Watchlist Pt. 9 $NXDR $GLSI $GIPR $RPTX $SOAR Let's Find a 1000%+ Runner this Week

0 · Reply

littleharoldeh Dec. 28 at 4:50 PM

$RPTX So what's the point of investing here if they are gonnna delist and only gonna get $1.82 a share

1 · Reply

Freshyone Dec. 26 at 4:39 PM

$RPTX ~ Whales coming for 2.66 break🐳🎉

0 · Reply

Freshyone Dec. 26 at 4:29 PM

$RPTX ~ Breakout watch!👀

0 · Reply

Mervolo Dec. 26 at 3:10 PM

$LAZR $LAZRQ 🤷‍♀️🤷‍♀️🤷‍♀️somebkdy keeps on buying. Thnk we can fo better than ,17 though. They say otc gets crays o 🤞🏽🤞🏼🤞🏽🤞🏼🤞🏽. Like getting to sleep in though👍👍👍 $RPTX looks like she holding levels since wedns spike so that s hopeful. Longer sideways, higher upways🙏🙏🙏. Just needs more vol $CANF saw earlier and looked tempting hut then saw that rs news and thought it might be a trap to carry longs into that Also thought about $ATPC and $NCL . Guess shoudla taken ncl weds 🤷‍♀️ Think we need to catch up on some slllleeeeep. Dunno if some moves gonna be delayed cuz of yesterday beingnoff but we ll play it by ear. But a nap sounds too good.

0 · Reply

RyaKelly Dec. 26 at 12:25 PM

$RPTX biotech low attention base forming needs confirmation

0 · Reply

VentureDebtV Dec. 25 at 7:31 AM

$RPTX Strategic positioning matters less than consistent throughput, given the heightened sensitivity to timeline slippage. Shortfalls would likely reprice expectations quickly.

0 · Reply

topstockalerts Dec. 24 at 8:04 PM

Repare Therapeutics announced a definitive asset purchase agreement with Gilead Sciences under which Gilead will acquire Repare’s Polθ ATPase inhibitor, RP-3467. Repare will receive up to $30 million in total consideration, including a $25 million upfront payment and up to $5 million tied to the completion of specific technology transfer activities. Management described the deal as the most significant of Repare’s three portfolio transactions this year, highlighting the strategic fit between RP-3467 and Gilead’s oncology R&D capabilities. The transaction follows Repare’s recent agreement to be acquired by XenoTherapeutics and Xeno Acquisition Corp. The upfront payment from Gilead has boosted Repare’s cash balance, increasing the estimated cash payout to shareholders in the Xeno acquisition to about $2.20 per share, up from prior expectations. $RPTX $GILD

0 · Reply

Freshyone Dec. 24 at 7:16 PM

$RPTX ~ Radar..Incoming after hours!🔥

0 · Reply

Mervolo Dec. 24 at 6:12 PM

$LAZR oh man, guess we shoulda bought more at ,13 :( glad to see the movement but sad we didn t load more boat today $RPTX hoping ah or fri will bring more ppl. Thouhht $GILD tying in would cause more of a rally hut if we alreadya tarted celebrating, pretty sure wally boys ready to call it a day and get to that offica partayyyyy $MWG nice little bounce there. Again, offered some decent scalps but, guess that s why they restrixt these to call ins. Oh wells Looking to rptx for ah maybe somethjng since lazr gonna go quiet at bell. Trying to rearrange the studio. Let s see if we can t get some new pieces rollin thise week

0 · Reply

AKIREICH Dec. 24 at 5:59 PM

$RPTX FRIDAY IT WILL GO DOWN 10%

0 · Reply

topstockalerts Dec. 24 at 5:59 PM

$RPTX making a solid move..

0 · Reply

BullishBee Dec. 24 at 5:14 PM

The following setups were identified and successfully reached their projected profit zones today and more. $ELOG | Entry: $1.98 -> Target: $2.18 (+10.0%) $HXHX | Entry: $1.02 -> Target: $1.12 (+10.0%) $SOBR | Entry: $2.63 -> Target: $2.89 (+10.0%) $RPTX | Entry: $2.44 -> Target: $2.57 (+5.4%) We focus on high-probability setups with defined risk parameters. Founder's Discount Active 🐝 Link in Bio.

0 · Reply

SuperGreenToday Dec. 24 at 4:45 PM

$RPTX Share Price: $2.57 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.13 – $0.16 Target Zone: $0.21 – $0.26 Potential Upside: 55% ROI Time to Expiration: 204 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

iWinnnnn Dec. 24 at 4:34 PM

$RPTX it’s all fake walls.

0 · Reply

Market Cap	110.79M
Revenue (ttm)	53.48M
Net Income (ttm)	-84.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-158.36%
Debt to Equity Ratio	0.00

Volume	1,427,409
Avg Vol	1,053,920
Day's Range	N/A - N/A
Shares Out	43.11M
Stochastic %K	82%
Beta	0.97
Analysts	Sell
Price Target	$3.00